E. Cho

发表

Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung

S. Park, S. Ha, Jae-Ik Lee, 2009, Journal of Korean medical science.

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Ying Cheng, E. Cho, S. Ramalingam, 2019, Clinical Cancer Research.

Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer

E. Cho, E. Kim, J. H. Kim, 2018, European journal of cancer care.

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer

Young Saing Kim, E. Cho, Eun Young Kim, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer.

S. Park, Jae-Ik Lee, Junshik Hong, 2007, Japanese journal of clinical oncology.

Ontogeny of natural killer cells and T cells by analysis of BCR–ABL rearrangement from patients with chronic myelogenous leukaemia

E. Cho, D. Heo, Y. Y. Lee, 2000, British journal of haematology.

High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral Blood Progenitor Cell Mobilization

J. Ahn, M. Ahn, E. Cho, 2005, The Korean journal of internal medicine.

Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel

E. Cho, J. Roh, Young-Min Son, 2011, Annals of dermatology.

Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer

S. Park, Jae-Ik Lee, Jinny Park, 2008, Cancer Chemotherapy and Pharmacology.

Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer

Junshik Hong, Jinny Park, E. Cho, 2011, Cancer Chemotherapy and Pharmacology.

A Phase II Study of W eekly Paclitaxel, C isplatin and C oncurrent Radiation T herapy for Locally -A dvanced U nresectable N on-Sm all C ell Lung C ancer: Early C losure due to Lack of E fficacy

E. Cho, D. Shin, J. H. Lee, 2010 .

A phase II study of weekly paclitaxel, cisplatin and concurrent radiation therapy for locally-advanced unresectable non-small cell lung cancer: early closure due to lack of efficacy.

S. Park, E. Cho, D. Shin, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

P. Fasching, F. Couch, K. Gelmon, 2021, European journal of cancer.

Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia

S. Park, Jinny Park, E. Cho, 2008, Journal of Korean medical science.

Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy

S. Park, Young Saing Kim, Junshik Hong, 2008, Quality of Life Research.

Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors

S. Park, E. Cho, D. Shin, 2005, Medical oncology.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

M. Ahn, Keunchil Park, S. Thongprasert, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)

J. Shih, Keunchil Park, E. Cho, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy

S. Park, Junshik Hong, Jinny Park, 2013, Cancer Chemotherapy and Pharmacology.

Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer.

S. Park, Young Saing Kim, Junshik Hong, 2010, Cancer research and treatment : official journal of Korean Cancer Association.

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin in 5-Fluorouracil-Pretreated Patients with Metastatic Colorectal Cancer.

M. Ahn, E. Cho, J. Lee, 2001, Cancer research and treatment : official journal of Korean Cancer Association.

Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.

E. Cho, M. Chung, E. Nam, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders

S. Park, E. Cho, D. Shin, 2006, The Korean journal of internal medicine.

Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy

S. Park, E. Cho, D. Shin, 2005, Cancer Chemotherapy and Pharmacology.

Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia

Junshik Hong, Jinny Park, E. Cho, 2015, Supportive Care in Cancer.

A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer

S. Park, Young Saing Kim, Junshik Hong, 2013, Cancer Chemotherapy and Pharmacology.

Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer

S. Ha, Jae-Ik Lee, Young Saing Kim, 2014, Tumor Biology.

Gemictabine plus carboplatin in patients with advanced non-small cell lung cancer

S. Park, E. Cho, D. Shin, 2005, Medical oncology.

ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

M. Ahn, Keunchil Park, T. Mok, 2012 .

Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer

S. Park, Junshik Hong, Jinny Park, 2011 .

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer

Tae You Kim, E. Cho, K. Jung, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma

Junshik Hong, Jinny Park, E. Cho, 2014, Leukemia & lymphoma.

A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer

E. Cho, D. Shin, M. Jung, 2014, Cancer Chemotherapy and Pharmacology.

A P hase II Study of P aclitaxel and C isplatin C om bination C hem otherapy in A dvanced N on-sm all-cell L ung C ancer

J. Ahn, E. Cho, J. H. Lee, 2003 .

Original Article Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type

Junshik Hong, Jinny Park, E. Cho, 2012 .

Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.

Junshik Hong, Jinny Park, E. Cho, 2012, International journal of clinical and experimental pathology.

Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma

Junshik Hong, Jinny Park, E. Cho, 2013, Acta Haematologica.

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing

Jae Woo Choi, Sung Sook Lee, Keunchil Park, 2019, PloS one.

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

M. Ahn, E. Cho, B. Cho, 2021, JTO clinical and research reports.

Treatment of Bone Metastasis

E. Cho, 2011 .

Heparin-Induced Thrombocytopenia (HIT) in Patients with Acute Coronary Syndrome: Incidence and Clinical Feature, Retrospective Study

S. Park, E. Cho, D. Shin, 2005 .

Association of the methylenetetrahydrofolate reductase polymorphism in Korean patients with childhood acute lymphoblastic leukemia.

M. Ahn, E. Cho, N. Kim, 2006, Anticancer research.

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

S. Park, E. Cho, D. Shin, 2005, BMC Cancer.

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.

E. Cho, S. Ramalingam, J. Vansteenkiste, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

E. Cho, S. Ramalingam, J. Vansteenkiste, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.

Sung Sook Lee, M. Ahn, E. Cho, 2020 .

Changes in quality of life during palliative chemotherapy for solid cancer

S. Park, E. Cho, D. Shin, 2005, Supportive Care in Cancer.

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis

Junshik Hong, Jinny Park, E. Cho, 2010, The Korean journal of hematology.

High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.

M. Ahn, E. Cho, J. H. Lee, 2003, Journal of Korean medical science.

High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma

M. Ahn, E. Cho, J. H. Lee, 2003 .

Randomized phase II trial of taxanes plus 5-fluorouracil for advanced gastric cancer

E. Cho, D. Shin, S. Park, 2005 .

Epirubicin (E), cisplatin (C) and capecitabine (X) in first-line chemotherapy for patients with advanced gastric cancer

E. Cho, D. Shin, S. Im, 2004 .

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma

S. Park, E. Cho, D. Shin, 2006, Cancer.

A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.

S. Park, E. Cho, D. Shin, 2006, Cancer research and treatment : official journal of Korean Cancer Association.

Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma

Junshik Hong, Jinny Park, E. Cho, 2013, Supportive Care in Cancer.

A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer

S. Park, E. Cho, D. Shin, 2008, Cancer Chemotherapy and Pharmacology.

Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia

E. Cho, D. Shin, J. H. Lee, 2003, The Korean journal of internal medicine.

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy

Junshik Hong, Jinny Park, E. Cho, 2014, Cancer science.

Vascular Complications in Patients with Essential Thrombocythemia

S. Park, E. Cho, D. Shin, 2006 .

Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia.

Jinny Park, E. Cho, D. Shin, 2010, Leukemia research.

Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.

S. Park, Jinny Park, E. Cho, 2008, International journal of radiation oncology, biology, physics.

A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

E. Cho, S. Im, K. Jung, 2015, Supportive Care in Cancer.

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Keunchil Park, E. Cho, Joo‐Hang Kim, 2021, BMC Cancer.

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Keunchil Park, E. Cho, Dong-Wan Kim, 2015 .

Ramosetron for the Prevention of Cisplatin-Induced Acute Emesis: A Prospective Randomized Comparison with Granisetron

H. C. Kim, E. Cho, Y. Bang, 2002, The Journal of international medical research.

Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation.

Junshik Hong, Jinny Park, E. Cho, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.

E. Cho, D. Shin, J. H. Lee, 2002, Journal of Korean medical science.

Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia

M. Ahn, E. Cho, J. H. Lee, 2022, The Korean journal of internal medicine.

Long-term follow-up results of cytarabine-contain-ing chemotherapy for acute promyelocytic leukemia Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia

M. Ahn, E. Cho, J. H. Lee, 2022 .

High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma

Yeon-Hee Park, E. Cho, J. H. Lee, 2005, Leukemia & lymphoma.

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Sin-Ho Jung, Ho Yun Lee, J. Ahn, 2016, Oncotarget.

Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer.

S. Ha, Junshik Hong, E. Cho, 2011, Lung cancer.

Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer

E. Cho, Y. Min, Jin-Hyoung Kang, 2013, Cancer Chemotherapy and Pharmacology.

Array-based Comparative Genomic Hybridization and Its Application to Cancer Genomes and Human Genetics

E. Cho, 2011 .

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

M. Ahn, E. Cho, S. Shreeve, 2021 .

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

M. Ahn, E. Cho, Dong-Wan Kim, 2020 .

Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

M. Ahn, E. Cho, Dong-Wan Kim, 2020 .

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

J. Ahn, M. Ahn, E. Cho, 2019, The Lancet. Oncology.

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

C. Schumann, N. Girard, G. Scagliotti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)

Ho Yun Lee, J. Ahn, M. Ahn, 2018, Journal of pathology and translational medicine.

Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer

E. Cho, 2016 .

Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer.

E. Cho, Y. Bang, D. Heo, 1998, Human gene therapy.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Chun-Ming Tsai, Lucio Crinò, Karen Kelly, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

M. Ahn, E. Cho, Siraj M. Ali, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

J. Ahn, M. Ahn, Keunchil Park, 2016, Oncotarget.

Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

S. Park, Young Saing Kim, Jinny Park, 2011, Medical oncology.

A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

Chun-Ming Tsai, Lucio Crino, Shaf Keshavjee, 2014 .

Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.

Junshik Hong, Jinny Park, E. Cho, 2015, Journal of geriatric oncology.

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.

M. Ahn, Keunchil Park, E. Cho, 2015, Lung cancer.

1275PEFFICACY OF EGFR TYROSINE KINASE INHIBITORS (EGFR TKIS) IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER EXCEPT BOTH EXON 19 DELETION AND EXON 21 L858R: A RETROSPECTIVE ANALYSIS IN KOREA.

M. Ahn, E. Cho, B. Cho, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors

Ha Yeon Lee, Young Saing Kim, Junshik Hong, 2014, Investigational New Drugs.

A randomized double-blind placebo-controlled study of low-dose intravenous Lorazepam to reduce procedural pain during bone marrow aspiration and biopsy.

S. Park, E. Cho, D. Shin, 2008, Pain medicine.

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Joon-Oh Park, J. Ahn, M. Ahn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.

Keunchil Park, E. Cho, D. Heo, 2006, Lung cancer.

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer

Young Saing Kim, E. Cho, D. Shin, 2022, American journal of clinical oncology.

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

M. Ahn, E. Cho, Dong-Wan Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Ha Yeon Lee, Sin-Ho Jung, J. Ahn, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer

Young Saing Kim, Junshik Hong, Jinny Park, 2016, The Korean journal of internal medicine.

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.

Keunchil Park, E. Cho, Dong-Wan Kim, 2019, Lung cancer.

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy

Young Saing Kim, Junshik Hong, Jinny Park, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia.

E. Cho, D. Heo, B. Kim, 2000 .

Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study

S. Park, E. Cho, D. Shin, 2006, The Korean journal of internal medicine.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second‐Line Treatment of Advanced Non–Small‐Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

E. Cho, S. Ramalingam, S. Dakhil, 2017, Clinical lung cancer.

Comparison of Microvessel Density Before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications: Multicenter Trial

Sung-Bae Kim, Q. Park, M. Ahn, 2002, International journal of hematology.

CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy

Junshik Hong, Jinny Park, E. Cho, 2012, Annals of Hematology.

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, Cancer Chemotherapy and Pharmacology.

Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer

S. Park, E. Cho, D. Shin, 2005, BMC Cancer.

Recurrent and metastatic trichilemmal carcinoma of the skin over the thigh: a case report.

S. Ha, Jinny Park, E. Cho, 2010, Cancer research and treatment : official journal of Korean Cancer Association.

Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.

J. Oh, S. Park, E. Cho, 2005, Japanese journal of clinical oncology.

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

M. Ahn, E. Cho, B. Cho, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Keunchil Park, Y. Ichinose, E. Cho, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer

S. Park, E. Cho, D. Shin, 2005, Oncology.

Clinical Features of Waldenstrom Macroglobulinemia in Korea

S. Park, E. Cho, D. Shin, 2004, The Korean journal of internal medicine.

Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.

S. Park, Junshik Hong, Jinny Park, 2008, Lung cancer.

Cytarabine and Idarubicin Induction Chemotherapy in Patients with Acute Myelogenous Leukemia

E. Cho, D. Shin, J. H. Lee, 2001 .

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Keunchil Park, E. Cho, Dong-Wan Kim, 2016 .

Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant‐specific inhibitor, in T790M‐positive NSCLC at the recommended phase II dose: 1300

E. Cho, Y. Min, J.-Y. Han, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

Prognostic significance of CT-emphysema score in patients with advanced squamous cell lung cancer.

Jeong Ho Kim, Young Saing Kim, E. Cho, 2016, Journal of thoracic disease.

Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy

Junshik Hong, Jinny Park, E. Cho, 2011, Leukemia & lymphoma.

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer

S. Park, Junshik Hong, Jinny Park, 2010 .

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.

Keunchil Park, E. Cho, Dong-Wan Kim, 2018, Lung cancer.

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Y. Ohe, B. Chewaskulyong, E. Cho, 2017 .

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

Sung-Bae Kim, Yeon-Hee Park, E. Cho, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

S. Park, E. Cho, D. Shin, 2006, Anti-cancer drugs.

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

S. Park, E. Cho, D. Shin, 2006, BMC Cancer.

The value of chest CT for prediction of breast tumor size: comparison with pathology measurement

Hye-Young Choi, Young Saing Kim, E. Cho, 2013, World Journal of Surgical Oncology.

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer

Young Saing Kim, Junshik Hong, Jinny Park, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.

J. Ahn, M. Ahn, E. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Ying Cheng, Y. Ohe, E. Cho, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study

S. Park, Young Saing Kim, Junshik Hong, 2008, Anti-cancer drugs.

Phase II clinical trial of SKI‐2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma

J. Ahn, E. Cho, Y. Bang, 1999, Cancer.

Prognostic Value of Metabolic Tumor Volume Estimated by 18 F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease

Kyung Hoon Hwang, Junshik Hong, Jinny Park, 2014, Nuclear Medicine and Molecular Imaging.

Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT

Jeong Ho Kim, Young Saing Kim, E. Cho, 2016, Supportive Care in Cancer.

Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma

Junshik Hong, Jinny Park, E. Cho, 2016, Blood research.

First-Line Chemotherapy with Irinotecan plus Capecitabine for Advanced Colorectal Cancer

J. Oh, S. Park, E. Cho, 2004, Oncology.

Lazertinib versus Gefitinib as First-line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

M. Ahn, E. Cho, Dong-Wan Kim, 2023, Cancer research and treatment.

LBA6_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2017 .

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results.

E. Cho, K. Bae, E. Attiyeh, 2018, Annals of Oncology.

Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study

Young Saing Kim, Junshik Hong, Jinny Park, 2015, Cancer Chemotherapy and Pharmacology.

A Phase II Study of Erlotinib as a First-Line Therapy for Patients with Non—Small-Cell Lung Cancer with Favorable Clinical Predictors

E. Cho, Sang-We Kim, Heung Tae Kim, 2008 .

Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer

E. Cho, K. Sung, H. Ahn, 2019, Annals of Oncology.

Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients.

E. Cho, D. Shin, S. Sym, 2016, Journal of palliative medicine.

Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.

N. Altorki, K. Kelly, E. Cho, 2014 .

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018 .

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

M. Ahn, Keunchil Park, E. Cho, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

E. Cho, E. Felip, A. Delmonte, 2022, Annals of Oncology.

Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first‐line therapy in advanced nonsmall cell lung cancer

S. Park, E. Cho, S. Jeong, 2007, Cancer.

Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer

Jinny Park, E. Cho, D. Shin, 2012, Cancer Chemotherapy and Pharmacology.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N. Altorki, K. Kelly, E. Cho, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.

J. Ahn, M. Ahn, E. Cho, 2018 .

A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.

J. Ahn, E. Cho, D. Shin, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

Second-line chemotherapy with mitomycin C and S-1 in patients with advanced gastric cancer.

E. Cho, S. Lee, D. Shin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Keunchil Park, Y. Ichinose, E. Cho, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of the Radiation Therapy Outcomes and Prognostic Factors of Thymoma

E. Cho, S. Sym, K. Lee, 2010 .